Transphorm GaN Moves into PC Gaming Market with CORSAIR
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and only qualified high voltage Gallium Nitride (GaN) semiconductors—today confirmed that its GaN FETs are used in CORSAIR’s new AX1600i Power Supply Unit (PSU). CORSAIR supplies the gaming community with high-performance products used in custom PCs. The company’s latest product establishes a new class of AC-to-DC PSUs, as it is the first to use GaN and achieves 99 percent efficiency. Transphorm’s GaN increases the PSU’s power output by 6.5 percent in an 11 percent smaller package at the same temperature.
GaN: The New Edge
The AX1600i uses Transphorm’s TPH3205WS 650V FETs in a bridgeless totem-pole power factor correction (PFC)—the topology that complements GaN’s performance and efficiency potential. With an increase of 6 percent within this topology, CORSAIR’s PSU efficiency now earns a better-than an 80 PLUS® Titanium rating. [Previous CORSAIR power supplies used Silicon (Si) superjunction (SJ) MOSFETs in a 2-phased interleaved PFC, reaching 93 percent efficiency.]
“Our objective was to take an already award-winning PSU and make it better,” explained Jon Gerow, PSU R&D Manager, CORSAIR. “We aimed to maximize output from any PC running on a 115V mains. To do this, we had to adopt innovative methods and materials. Transphorm’s GaN ultimately gave us the boost in performance, efficiency and size we wanted along with the high quality and reliability we needed to confidently release the AX1600i to our customers.”
After researching market-available GaN devices, CORSAIR chose Transphorm’s FETs as they enabled the AX1600i to deliver new benchmarks compared to the previous AX1500i:
- Power output: 1600W, 6.5 percent increase
- Size reduction: 20 mm shorter, 11 percent smaller
- Thermal impact: equivalent 50°C continuous output
- Audible noise impact: slower fan speed, less noise at full load
CORSAIR noted that Transphorm’s packaging also played a role in its selection process. The TPH3205WS comes in a commonly used TO-247 package, reducing some design complexity.
“CORSAIR’s brand is built on products that give our customers a competitive edge, inside and outside of the gaming PC. And, Transphorm’s GaN presented an invaluable opportunity to advance the PSU—to make it smaller, quieter, cooler, and, most importantly, more powerful,” added Gerow.
Collaboration: The Transphorm Edge
Transphorm’s commitment to high quality and reliability extends beyond the technology. Gallium Nitride devices are higher frequency, sometimes requiring different design techniques than previously used with Si. The company’s GaN experts collaborate regularly with customers to provide guidance and to identify areas of opportunity for future platform innovation and customer design resources.
Regarding the AX1600i project, Transphorm supported CORSAIR during both the prototyping and the design validation testing phases. CORSAIR tapped Transphorm’s teams on the ground in Shenzhen, China, and California, U.S.
Founded in 1994, CORSAIR supplies high-performance products purchased primarily by PC gaming enthusiasts who build their own PCs or buy pre-assembled customized systems. The company's award-winning products include fully-assembled PCs, DDR4 and DDR3 memory, computer cases, PC cooling products, gaming headsets, gaming keyboards, gaming mice, power supply units, USB flash drives, solid-state drives and system monitoring and control devices.
Transphorm designs and manufactures the highest performance, highest reliability GaN semiconductors for high-voltage power conversion applications. Holding one of the largest IP portfolios (600+ patents), Transphorm innovates at every development stage—design, fabrication, device, application support—to produce the only JEDEC and AEC-Q101 qualified FETs.
Heather Ailara, 845-424-6341
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Asuragen to Present at World CB & CDx Europe Summit in London, UK24.4.2018 12:00 | Pressemelding
Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that its senior vice president of commercial operations, Colin Hill, will chair a roundtable discussion during the 2018 World Clinical Biomarkers & Companion Diagnostic (CB & CDx) Europe Summit taking place May 1-3 in London, UK. The session will focus on the imminent changes to the regulatory environment in Europe and the implications for pharmaceutical and diagnostic companies collaborating to advance precision medicine. “Precision medicine is becoming a reality around the world, and the regulations that guide it are rapidly evolving,” said Hill. “It is essential that we build close collaboration between the pharmaceutical, medical device and in vitro diagnostics industry if we are going to successfully navigate this new environment. While our success will definitely leverage learnings from the US experience, we will have to broaden our thinking as w